Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.

A custom 30 G needle with a closed tip and side port shows equivalent performance to standard needles for anti-VEGF delivery.

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening diseaseNORWICH, England & ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

Shares in biopharmaceutical group Outlook Therapeutics ($OTLK) collapsed in pre-market trading after the U.S. Food and Drug ...

Age-related macular degeneration (AMD) is the leading cause of blindness among older adults. The exudative or ‘wet’ form of the disease is characterized by the growth of abnormal blood vessels from ...

Significantly fewer patients in the fluocinolone acetonide intravitreal implant group experienced recurrence of uveitis at 6 months compared with the sham group. The Food and Drug Administration (FDA) ...